TL;DR
The individual case safety report process starts with case intake and validation, followed by data entry, MedDRA coding, narrative writing, seriousness/expectedness assessment, quality checks, and submission to regulators within strict timelines. Strong case processing protects patient safety and supports regulatory compliance.
In pharmacovigilance, safety data doesn’t just “appear” in a database. It’s collected, reviewed, written, coded, assessed, and submitted through a workflow designed to protect patients and meet global regulatory expectations.
That’s why understanding the individual case safety report process matters so much, especially if you’re preparing for a drug safety role. An ICSR is not just a form. It’s a formal safety record that can influence signal detection, label updates, and in serious cases, regulatory action.
This guide breaks down case processing from the first moment a safety report is received to the point it’s submitted to health authorities.
What is an Individual Case Safety Report in pharmacovigilance?
An Individual Case Safety Report (ICSR) is a structured report of one patient’s adverse event or suspected adverse reaction associated with a medicinal product.
ICSRs are used globally to collect post-market and clinical safety data in a standardized format. Reporting standards are guided by frameworks such as ICH E2B(R3), which defines how ICSRs are structured and exchanged electronically across regulatory systems.
In practical terms, an ICSR is the foundation of pharmacovigilance. Without consistent, high-quality ICSRs, safety teams cannot reliably identify patterns or emerging risks.
Individual Case Safety Report Process Step 1: Case Intake and Triage
The first step in case processing in pharmacovigilance is case intake. Safety cases may come from many sources: healthcare professionals, patients, clinical trial sites, literature articles, social media monitoring, market research programs, or partner companies.
During intake, the team triages the case to determine:
- whether it is valid
- whether it is serious
- whether it involves a product in scope
- whether it triggers expedited reporting timelines
This early step is also where duplicates are flagged, attachments are logged, and follow-up needs are identified.
Step 2: Validity Check (Does This Qualify as a Safety Case?)
What information is required for a valid safety case? Most regulatory frameworks recognize four minimum criteria for a valid ICSR:
- An identifiable patient
- An identifiable reporter
- A suspect product
- An adverse event or reaction
If any of these elements are missing, the report may be documented as “non-valid,” but it still often requires follow-up attempts depending on the company’s SOPs.
As you’ll discover in pharmaceutical training, this is one of the most important steps in the entire workflow because validity triggers the clock for regulatory reporting timelines.
Step 3: Data Entry and Medical Coding (MedDRA + WHODrug)
Once a case is validated, case processors enter structured information into the safety database. This includes:
- patient demographics
- medical history
- suspect and concomitant products
- event details and outcome
- lab results and clinical notes
- reporter details and source
Then comes coding. Events are coded using MedDRA terminology, and products are typically coded using WHODrug. These coding standards allow safety teams and regulators to analyze reports consistently across countries and products.
Step 4: Narrative Writing (Where Quality Makes or Breaks the Case)
How to write an individual case safety report depends heavily on your company’s templates and regulatory expectations, but the goal is always the same: create a clear, medically accurate story.
A strong narrative usually includes:
- Why was the case reported
- A timeline of the event
- Relevant medical history
- Suspect product details (dose, start/stop dates)
- Event outcome and treatment
- Reporter assessment, if available
A narrative should read like a factual medical summary, not a dramatic story, and not a copy-paste of raw notes. Clarity matters because narratives are reviewed by auditors, medical reviewers, and regulators.
Step 5: Seriousness and Expectedness Assessment
How do pharmacovigilance teams assess seriousness and expectedness?
Seriousness is assessed using regulatory seriousness criteria such as:
- death
- life-threatening event
- hospitalization (or prolongation)
- disability/incapacity
- congenital anomaly
- other medically important condition
Expectedness is assessed by comparing the reported event against the product’s reference safety information (RSI), such as the Company Core Data Sheet (CCDS) or label.
This step is critical because seriousness and expectedness determine whether the case is reportable, how quickly it must be submitted, and whether it may contribute to signal detection.
Step 6: Quality Review and Regulatory Submission
Before submission, cases typically undergo:
- completeness checks
- query resolution
- duplicate review
- narrative quality review
- medical review (depending on seriousness and company SOP)
Then, the case is submitted electronically to regulatory systems (such as EudraVigilance in the EU). Regulatory submission requirements vary by region, but the global exchange format is aligned through ICH E2B(R3).
Common Mistakes in Case Narratives and How to Avoid Them?
What are common mistakes in case narratives, and how do you avoid them? The most common narrative mistakes tend to fall into a few patterns: missing timelines, unclear drug-event relationships, contradictions between fields and narrative, and overly vague wording.
The best way to avoid these errors is to write narratives the way a regulator would read them:
- Keep the timeline chronological
- Use consistent terms across the case
- Avoid assumptions or diagnoses unless stated by the reporter
- Include key negatives only when clinically relevant
- Make sure the narrative matches the coded terms and structured fields
How Do Regulatory Reporting Timelines Work for Safety Cases?
Reporting timelines depend on the type of case and jurisdiction, but serious cases typically have the fastest reporting requirements.
In general:
- Serious cases require expedited reporting
- Non-serious cases are usually submitted periodically
- Clinical trial cases may follow different reporting rules than post-market cases
Because regulators may audit submission timing, the case intake date and awareness date must be tracked precisely. Agencies like the FDA guide postmarket reporting requirements, and the EMA outlines ICSR submission expectations through EudraVigilance.
Why Strong Case Processing Creates Better Pharmacovigilance Careers
Case processing is sometimes described as “entry-level pharmacovigilance,” but in practice, it’s one of the best training grounds in the industry. It builds the exact habits that employers value: accuracy, documentation discipline, clinical thinking, and regulatory awareness.
If you’re exploring pharmacovigilance as a long-term career path after completing your pharmaceutical courses, understanding the individual case safety report process gives you a strong foundation for future roles in medical review, signal detection, risk management, and regulatory safety reporting.
Would you like to explore opportunities in the pharmaceutical industry?
Contact the NeuAge Institute for more information.
Key Takeaways
- ICSRs are structured safety reports used globally for regulatory pharmacovigilance
- A valid case requires a patient, reporter, suspect product, and event
- Case processing includes intake, validation, coding, narrative writing, and medical review
- Seriousness and expectedness drive reporting timelines
- High-quality narratives reduce errors and support compliance
FAQ: Individual Case Safety Report Process
What is an Individual Case Safety Report in pharmacovigilance?
An Individual Case Safety Report (ICSR) is a structured report of one patient’s adverse event or suspected adverse reaction associated with a medicinal product.
What information is required for a valid safety case?
Most regulatory frameworks recognize four minimum criteria for a valid ICSR:
- An identifiable patient
- An identifiable reporter
- A suspect product
- An adverse event or reaction
How do pharmacovigilance teams assess seriousness and expectedness?
Seriousness is assessed using regulatory seriousness criteria such as:
- death
- life-threatening event
- hospitalization (or prolongation)
- disability/incapacity
- congenital anomaly
- other medically important condition
What are common mistakes in case narratives, and how do you avoid them?
The most common narrative mistakes tend to fall into a few patterns: missing timelines, unclear drug-event relationships, contradictions between fields and narrative, and overly vague wording.
How do regulatory reporting timelines work for safety cases?
Reporting timelines depend on the type of case and jurisdiction, but serious cases typically have the fastest reporting requirements.
